Latest Updates of Companies in the Drug Desensitization Market with Forecast 2026-2035
Company Latest Updates
| Company | Headquarters | Latest Update |
| ALK-Abelló A/S | Denmark | In June 2025, ALK presented comprehensive data on two novel paediatric AIT tablets and a nasal adrenaline spray. |
| Stallergenes Greer | Switzerland | Stallergenes Greer advances allergy treatment via clinical trials and real-world studies and produces high-quality data. |
| Allergy Therapeutics plc | United Kingdom | Allergy Therapeutics plc made significant strides in the progress of its allergy desensitization portfolio. |
| HAL Allergy Group | United States | HAL Allergy is included in an ambitious clinical trial program to advance medicines with blockbuster strength for respiratory allergies. |
| Merck KGaA | Germany | Merck KGaA is seriously focused on increasing its oncology and immunology portfolio, with noteworthy activity in developing antibody-drug conjugates and advancing targeted therapies for immune-driven diseases. |
| HollisterStier Allergy | United States | Jubilant HollisterStier Allergy is pleased to announce that it has received zero observations following a recent inspection conducted by the United States Food and Drug Administration, Center for Biologics Evaluation and Research (CBER). |
Value Chain Analysis
Research and Development:
- Research and Development (RandD) in drug desensitization (DD) is a multi-stage process that transitions from laboratory models to healthcare validation and protocol optimization.
- Key Players: Inmunotek and Laboratorios LETI, S.L.
Manufacturing Processes:
- Major manufacturing processes for drug desensitization refer to the dedicated pharmaceutical compounding and preparation steps needed to create the specific, low-concentration services used in healthcare protocols.
- Key Players: Allergopharma GmbH and Co. KG
Patient Services:
- Drug desensitization services offer a controlled, inpatient, or dedicated outpatient process for patients with severe allergies to necessary medicines.
- Key Players: ALK-Abelló A/S and Stallergenes Greer LLC
Market Forecast
The global drug desensitization market size was estimated at USD 670.03 million in 2025 and is predicted to increase from USD 724.57 million in 2026 to approximately USD 1465.41 million by 2035, expanding at a CAGR of 8.14% from 2026 to 2035.
Recent Developments in the Drug Desensitization Market
- In November 2025, Zealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize petrelintide as a future foundational therapy for people with overweight and obesity
- In September 2025, Regeneron Pharmaceuticals, Inc. announced results evaluating its first-in-class investigational allergen-blocking antibodies in allergen-challenge Phase 3 trials in adults with moderate-to-severe cat or birch allergies. Both trials met their respective primary and key secondary endpoints. Data from the Phase 3 trials will be presented at an upcoming healthcare conference and will inform confirmatory Phase 3 trials.
- In September 2025, BioMarin Pharmaceutical Inc. announced new data characterizing the efficacy and safety of PALYNZIQ for the treatment of adolescents with phenylketonuria (PKU), which were presented at the 15th International Congress of Inborn Errors of Metabolism.
One dashboard, complete Drug Desensitization Market intelligence at your fingertips - Access the Dashboard
Keypoints
- Company Overview
- Locations Subsidiaries/Geographic reach
- Key Executives
- Company Financials
- Patents registered
- SWOT Analysis
- Applications Catered
- Strategic collaborations
- Recent Developments
- Competitive Benchmarking
